Content area
Full Text
Menevit has been promoted for healthy male sperm for many years, largely on the basis of the Tremellen paper which demonstrated a marginal (p=0.046) improvement in pregnancies at 3 months.1 Uncertainties regarding the conclusions from the Tremellen paper include: Tremellen was the inventor of Menevit; there was no significant improvement in DNA fragmentation or progressive sperm motility, which are considered to be surrogate targets for the antioxidants contained in Menevit; and 3-month live birth endpoint...